Specific treatment of reduced insulin release in type 2 diabetes using yohimbine

• Conditions: Type 2 diabetes mellitus; MedDRA version: 16.1Level: LLTClassification code 10045242Term: Type II diabetes mellitusSystem Organ Class: 100000004861; Therapeutic area: Diseases [C] - Hormonal diseases [C19]

• Registration Number: EUCTR2010-018604-85-SE
• Lead Sponsor: und University

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2011-06-29
• Last Update Posted: 10 February 2014

Recruitment & Eligibility

• Status: Authorised-recruitment may be ongoing or finished
• Sex: All
• Target Recruitment: Not specified

Inclusion Criteria

Written informed consent
Males between 18 and 70 years; postmenopausal women below 70 years
C-peptide 0.35-1.8 nmol/L
HbA1c = 80 mmol/mol according to IFCC
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range 280
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range 280

Exclusion Criteria

Ongoing treatment with insulin, other injected antidiabetic treatment, or oral antidiabetic treatment except metformin
GAD antibodies
Dysregulated hypertension
Glaucoma
Known coronary artery disease or arrythmia
Known current or previous ventricular or duodenal ulcer
Known anxiety syndrome
Ongoing treatment with alpha- or beta-adrenergic blockers
Creatinine > 130 micromol/L
Liver failure
Mental disability

Study & Design

• Study Type: Interventional clinical trial of medicinal product
• Study Design: Not specified